Login to Your Account


Raxone puts on red light, EU policing DMD results; Santhera decision due Q3

By Randy Osborne
Staff Writer

Friday, May 19, 2017

Santhera Pharmaceuticals AG's latest European holdup in getting the label expanded for Raxone (idebenone) did not dampen the enthusiasm of RBC Capital analyst Matthew Eckler, who allowed that the news "adds a wrinkle to the story" but predicted the nod for Duchenne muscular dystrophy (DMD).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription